Introduction:
Nowadays the rate of premature birth called "preterm labor" is high causing many problems for both the mother and the baby (1) . Preterm labor is the leading cause of death in a newborn without anomalies. After birth defects, premature labor is the second main cause of neonates' mortality. This imposes a high economic and psychological cost to the society (2) . Preterm labor occurs in 11.8% of various races (3) . Babies born before 24 weeks gestation do not survive and the ones who survive are less likely to be healthy and are at increased risk of health problems (4) . It also increases the risk of respiratory distress syndrome (RDS) among these group caused by lack of surfactants secretion. However fetus at 26-34 weeks that complete dosage of betamethasone 48h before delivery, the mortality and RDS morbidity rates are significantly decreased. Antenatal glucocorticoid administration can significantly reduce RDS and other problems including intra ventricular hemorrhage (IVH), patent ductus arteriosus (PDA), pneumothorax, necrotizing enter colitis (5). Infants born preterm are at risk of various neurological complications. Neurodevelopment squeal in preterm infants include cerebral palsy, seizures, hydrocephalus, blindness, deafness and cognitive impairment. The risk of an adverse outcome increases with decreasing gestational age at birth (2) . Early morbidity and prognostic variables that contribute to adverse neurodevelopment outcomes are include: grades 3-4 intraventricular hemorrhage, necrotizing entro colitis, periventricular leukomalacia, neonatal infections and Broncopulmonary dysplasia (6) . At school age VLBW newborns have poorer physical growth and cognitive function as well as school performance (3). The final goal of treating preterm labor is to prolong of pregnancy in the patients and delay delivery for at least 48 hours so it allows corticosteroid treatment to improve fetal lung maturity (1) . Much research has been conducted regarding the prevention of or minimizing the complication of premature labor. Various treatments have also been proposed among this group of patients.
Although pharmacological suppression of contractions is the most common treatment (7), there is still disagreement on the best method of treatment.
Some pharmacological compounds are used to suppress uterine contractions in women with preterm labor (8) . The medicines used to suppress preterm labor are including Ritodrine, Magnesium sulfate and Calcium channel blockers (1). The effects of relaxant agents in suppression of preterm labor has not been proven, yet (9) . Preterm labor is the main reason for early death among 85% of premature infants (10) . previous studies about this subject and necessity of this study is to compare the effects of magnesium sulfate and nefidipine to suppress preterm labor. We also evaluate fetal and neonatal complications due to magnesium sulfate and nefidipine administration.
Material & Methods:
This was a double-blind, randomized clinical trial conducted in Alzahra and Taleghani Medical Educational Centers in Tabriz. Research samples were 80 pregnant women that allocated randomly in 2 groups by use of rand list soft ware and block of 3 and 6.Inclusion criteria's included women with gestational age of 26-34 weeks having regular uterine contractions lasted about 20-30 seconds, at least one contraction every 10 minutes, with cervical dilation of (maximum) 2-3 cm, cervical effacement of 50% or less, feeling of pressure in the pelvis, low back pain and vaginal discharge. Entering the labor room written informed consent was taken by the all participants. For the women in magnesium sulfate group an initial loading dose of 4g was given intravenously and then 2g every one hour provided that a patellar reflex was present, urine output during the proceeding half an hour exceeds 30 ml, and respiration exceeds 12 per minute. For the patients in the nefidipine group initially received 20 mg of oral nefidipine, 20mg nefidipine was given again if the contractions continued after half an hour. If not, subsiding 20 mg was continually administered every 3-8 hours up to 48 hours. Treatments were discontinued ISSN 2330-4456 if contractions progressed. The contraindications of administration of nefidipine included: maternal hypotension (systolic BP less than 9mmHg), Liver dysfunction, recent intake of magnesium sulfate. The data from the study were analyzed using statistical descriptive method (frequency, percentage and mean± standard deviation), statistical tests (independent sample t-test),
and Chisquare test. In this study P<0.05 was considered statistically significant.
Results:
In the magnesium sulfate group, decreasing the frequency of fetal movement was 27.5%. While heart rate reduction from baseline was 57.5% and fetal heart rate exchanges was decreased in 37.5%. None of these changes were seen in the nefidipine group. Comparison showed significant difference in fetal heart rate and reduction of fetal movement, changes in baseline state and heart rate changes. (Table -1) No significant difference in neonatal outcomes was showen between the two groups (the first and fifth minute Apgar score, admission to NICU, Sao2, PH, PCO2, PO2, HCO2, BE). (Table -2 ) Discussion:
Results of the study showed that the significant differences in the drug effects on fetal movement as well as baseline fetal heart rate. In the magnesium sulfate group the baseline fetal heart rate (signed in monitoring device) dropped by 10-20 beats. In addition, the heart rate changes were less than the fetal heart rate, appears similar to sinusoidal pattern. Hallak et al (1999) conducted a study titled: "The effects of magnesium sulfate on fetal heart rate parameters". Findings showed that magnesium sulfate administration resulted in decreased fetal heart rate baseline values and variability which was consistent with the present study (11) . According to the results of a study by Fujimori et al (2004) , "The effects of magnesium sulfate on behavioral activities of fetal goats", incidence of fetal heart rate accelerations during magnesium sulfate infusion was significantly decreased, that these are also consistent with the current study (12) .
Regarding arterial blood gas (ABG) measurement, there was no significant statistical difference between two groups in the first and fifth minute Apgar score, admission to NICU, Oxygen saturation, PH, CO2, PO, HCO3, BE. Edwin & Sabaratnam (2005) reviewed 12 researches and then published an article titled: "Recent advances in management of preterm labor". They concluded that calcium channel blockers can reduce the incidence of respiratory distress syndrome, necrotizing enter colitis, intraventricular hemorrhage and neonatal jaundice. In this study magnesium sulfate infusion resulted in high fetal complications (6) . These results are consistent with our findings. This difference is from the fact that, in our study ABG was only measured in those neonates who had failed treatment and delivery was unavoidable. Before completion of Betamethason intake, all of the 21 preterm neonates were born. Therefore, all of them were admitted to NICU with respiratory distress syndrome. But in the study by Edwin et al, all of the newborns were assessed after birth regardless whether born before or after completion of Betamethasone intakes.
Conclusion :
In this study we compared effects of magnesium sulfate and nefidipine for suppress of preterm labor. Findings showed that nefidipine was more efficient than magnesium sulfate in suppress of uterine contractions. Yet, nefidipine is associated with improved fetal and neonatal outcomes such as fetal heart rate and fetal movement, changes in baseline state and heart rate changes compared to the magnesium sulfate agent; thus the difference is significant. We suggest that nefidipine use for suppression of preterm labors in Hospitals.
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